

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office' Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/739,451	12/17/2003	Dennis Rowe	RPS6127-US	9345
74432 Fitzpatrick Cel	7590 11/16/2007		EXAMINER	
Fitzpatrick Cella (Catalent) 30 Rockefeller Plaza			SAMALA, JAGADISHWAR RAO	
New York, NY	10112		ART UNIT	PAPER NUMBER
		•	1618	
	·		MAIL DATE	DELIVERY MODE
		,	11/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/739,451	ROWE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Jagadishwar R. Samala	1618				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period was realiure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
Responsive to communication(s) filed on 2a) ☐ This action is FINAL . 2b) ☑ This 3) ☐ Since this application is in condition for allowan closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) ⊠ Claim(s) 1-3,6-8,10 and 12-18 is/are pending ir 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-3,6-8,10 and 12-18 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the original transfer and the correction of	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 10/18/2004.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	nte				

Application/Control Number: 10/739,451 Page 2

Art Unit: 1618

DETAILED ACTION

Status of Application

1. Applicant's election of group I, claims 1-18 in the reply filed on 09/26/2007 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Applicant's election of species with traverse of the plasticizer is glycerine as set forth in claim 3 and the gelatin is a combination of fish and bovine gelatins as set forth in claim 10 is acknowledged. The traversal is on the ground(s)that search in not burden, since the bovine gelatin alone or a combination of a plurality of fish gelatins as the gelatin component would not impose any undue burden. This is not fond persuasive because different forms of gelatin may have different physical properties such as low gelation temperature, and high solution viscosity and the like, which changes the composition, function and utility of the respective soft gelatin capsule. The requirement is still deeded proper and is therefore made Final. And claims 1-3, 6-8, 10, 12-18 read on the elected species and are presented for examination.

Drawing(s)

2. The drawing(s) filed on 12/17/2003 has been acknowledged.

Information Disclosure Statement

3. The Information Disclosure Statement filed on 10/18/2004 has been received and entered. The references cited on the PTO-1449 form have been considered by the examiner and a copy is attached to the instant office action.

Application/Control Number: 10/739,451 Page 3

Art Unit: 1618

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 3. Claims 1-3, 6-8, 10, 12-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Borkan et al. (US 4,935,243) or Hassan et al. (WO-03/090726) in view of Tindal et al. (US 6,387,400) and Tanner et al. (US 6,340, 473).

Borkan et al. teach a chewable, edible soft gelatin capsule which comprises a shell comprising about 20-45% gelatin; about 17.5-35% plasticizer; about 15-30% water and about 5-25% of a hydrogenated starch hydrolysate effective to render said shell dispersible and soluble in the mouth of the user (see abstract and col. 2, lines 51-58).

The disclosed gelatin include fish gelatine (type A) and bovine gelatin (type B) to obtain a gelatin with the requisite viscosity and bloom strength range from 6-300 (see

Application/Control Number: 10/739,451

Art Unit: 1618

col. 3 lines 30-45). The disclosed plasticizer include glycerin (col.5, lines 53-56). The disclosed modified starch includes a hydrogenated starch hydrolysate in a weight percentage of about 5-25% (see col. 5, lines 12-15).

Borkan et al. explain that chewable, edible soft gelatin capsule are beneficial because they are capable of convenient delivery vehicle for a unit dosage of the active ingredients. Soft gelatin capsules allow these users to easily chew and ingest the active ingredients within the capsules in a palatable form.

Hassan et al. teaches a soft chewable capsule. The disclosed chewable capsule includes a gel-forming polymer, a plasticizer, a polymer modifier, and water. The disclosed gel-forming polymer composition comprising different types of gelatins from different sources e.g. acid and lime bone bovine gelatins, skin bovine gelatin and fish gelatin (see abstract and page 4, lines 9-12). The disclosed plasticizer includes sorbitol or glycerol, sorbitol, maltitol, xylitol, and combination thereof (see page 2, lines 26-28).

Hassan et al. explain that chewable soft capsule useful as a dosage delivery system. The soft capsule, exhibits a consistency, texture and other organo-leptic properties found desirable in a chewable capsule.

The Borkan et al. and Hassam et al. reference differs from the instant case only in that it does not disclose some of the excipients claimed, i.e. hydroxypropylated starch. However, use of these excipient was well known in the art at the time the instant application was filed, as evidenced by the Tindal et al. reference.

Application/Control Number: 10/739,451

Art Unit: 1618

Tindal et al. teach a process for making soft gelatin capsules comprising a gelatin, a plasticizer, and an anti-adhesion agent (see abstract; col. 3, lines 42-50 and col.5, lines 33-42).

The disclosed gelatin include fish gelatin (col. 3, line 49). The disclosed plasticizer include glycerin (col. 5, line 38). The disclosed anti-adhesion agents include modified starch like hydroxypropylated starches (col. 3, lines 424-50).

Tindal et al. explain that soft gelatin capsules are beneficial because they are capable of retaining liquid fill material, unlike conventional hard shell capsules.

Tanner et al. teaches compositions for the manufacturing of soft capsules (see abstract).

The disclosed capsule includes plasticizer such as glycerin and sorbitol (see col. 6, lines 28-30). The disclosed modified starch such as hydroxypropylated tapioca starch and pregelatinized starch (see col. 6, lines 40-45). The disclosed capsule includes shell thicknesses varying from about 0.024 to 90.1778 (see col. 13, lines 18-22).

It would have been prima facie obvious to a person having ordinary skill in the art at the time of the invention to develop a edible, chewable, soft gelatin capsule comprising a gelatin, plasticizer, modified starch and water. When these references are taken together, one would have been motivated to extend Tindal and Tanner's teaching to add hydroxypropylated starch, which may impart acceptable physical characteristics to the soft gel capsule when in an equilibrium state to maximize therapeutic efficacy. As suggested by cited references, one would have reasonably expected successful addition of secondary excipients (hydroxypropylated starch) because effectiveness,

Application/Control Number: 10/739,451

Art Unit: 1618

extra benefits (.e. consistency, economical to manufacture and increase patient comfort) and safety are already well proven and are well suggested by the latter references.

One would have been motivated to do so, with reasonable expectation of success because it is always desirable to have extended therapeutic modalities to improve patient's compliance by enhancing patient satisfaction and increasing the selection option. The techniques and skills required for making such substitution is conventional knowledge or well within the skills of ordinary artisan as evidenced by these references cited.

One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities, and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

Conclusion

- 1. No claims are allowed at this time.
- 2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jagadishwar R. Samala whose telephone number is (571)272-9927. The examiner can normally be reached on 8.30 A.M to 5.00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571)272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/739,451 Page 7

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jagadishwar R Samala Examiner Art Unit 1618

Zohreh Fay Primary Examiner

Art Unit 1618